Table 2.
Cox regression analysis for survival outcomes
| Biochemical recurrence-free survival | Progression-free survival | Overall survival | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariable | Multivariable | Univariable | Multivariable | Univariable | Multivariable | |||||||
| HR (95% CI) |
P-value | HR (95% CI) |
P-value | HR (95% CI) |
P-value | HR (95% CI) |
P-value | HR (95% CI) |
P-value | HR (95% CI) |
P-value | |
| Protocol |
0.82 (0.57–1.16) |
0.69 | – | – |
0.83 (0.55–1.25) |
0.77 | – | – |
0.40 (0.20–0.81) |
0.030* | – | 0.21 |
| Age |
0.96 (0.93–1.00) |
0.027* |
0.97 (0.94–1.00) |
0.064 |
0.99 (0.96–1.03) |
0.70 | – | – |
1.04 (0.98–1.11) |
0.21 | – | – |
| Initial PSA |
1.00 (1.00–1.01) |
0.12 | – | – |
1.00 (1.00–1.00) |
0.97 | – | – |
1.00 (0.99–1.00) |
0.84 | – | – |
|
Clinical T stage Reference; 2≦ |
1.00 (0.57–1.68) |
0.99 | – | – |
0.98 (0.52–1.77) |
0.95 | – | – |
1.06 (0.41–2.48) |
0.89 | – | – |
|
Gleason score Reference; 8≦ |
2.58 (1.57–4.38) |
0.0002* |
2.36 (1.31–4.37) |
0.0042* |
2.13 (1.26–3.68) |
0.0046* |
1.52 (0.84–2.82) |
0.17 |
1.13 (0.53–2.43) |
0.75 | – | – |
|
NCCN risk Reference; high |
1.91 (1.14–3.12) |
0.015* |
1.29 (0.71–2.29) |
0.39 |
3.66 (2.14–6.22) |
<0.0001* |
3.01 (1.66–5.44) |
0.0003* |
2.91 (1.30–6.30) |
0.011* |
3.56 (1.63–7.75) |
0.001* |
| PSA at HDR-BT |
1.01 (1.01–1.02) |
0.0018* |
1.01 (1.00–1.02) |
0.073 |
1.00 (0.99–1.01) |
0.45 | – | – |
0.92 (0.45–1.01) |
0.40 | – | – |
| Time to PSA nadir |
1.02 (1.01–1.04) |
0.0055* |
1.02 (1.00–1.04) |
0.042* |
1.00 (0.98–1.02) |
0.73 | – | – |
1.00 (0.97–1.02) |
0.98 | – | – |
| PSA nadir |
3.71 (1.65–6.40) |
0.0049* |
2.83 (1.40–5.70) |
0.029* |
4.41 (2.23–8.72) |
0.0032* |
3.98 (1.68–7.39) |
0.005* |
2.29 (0.01–9.36) |
0.60 | – | – |
| C index with NCCN risk | 0.66 | 0.69 | 0.71 | |||||||||
| C index without NCCN risk | 0.64 | 0.65 | 0.63 | |||||||||
CI confidential interval, HDR-BT high-dose-rate brachytherapy, HR hazard ratio, NCCN National Comprehensive Cancer Network, PSA prostate-specific antigen
*statistically significant p-value